Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade
Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.
You may also be interested in...
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.
Alnylam’s stock fell more than 40% in after-hours trading following the decision to end development of revusiran based on an imbalance of deaths in the Phase III ENDEAVOR clinical trial, but executives see no read-through to the rest of the company’s RNAi platform.